Project Grant R44HL122028

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $665,000 to support the development and clinical testing of MT-601, a novel multi-tumor associated antigen (MTAA)-specific T-cell therapy for the treatment of non-Hodgkin lymphoma (NHL). The key objectives of this project are to manufacture the MT-601 product and conduct a Phase 1 clinical trial evaluating its safety and efficacy in NHL patients who have relapsed after prior CD19...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $781,436 to Cold Spring Harbor Laboratory to conduct research on optimizing anti-NMDAR antibodies for the treatment of triple-negative breast cancer (TNBC). The key objectives of this 5-year project are to: Establish a preclinical mouse model with NMDAR-positive TNBC to evaluate anti-NMDAR antibody therapies. Use single-particle cryo-electron microscopy to screen for...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mink Therapeutics Inc., a clinical-stage biopharmaceutical company in Lexington, MA. The grant funding will support preclinical studies to evaluate the efficacy of Mink's investigational cellular immunotherapy product, Agent-797, in reducing graft-versus-host disease (GVHD) and improving immune engraftment following...

This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $857,315 to Creosalus Inc. to conduct a first-in-human clinical study evaluating the safety and efficacy of the company's Porous Brain Infusion Catheter (PBIC) system for convection-enhanced delivery of therapeutics to recurrent Grade 3-4 glioma patients. The primary objective is to assess the PBIC's safety profile and its ability to achieve significantly greater coverage of enhancing...

This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), provides $730,000 in funding to Human Cell Co to determine the efficacy and mechanism of action of their proprietary nerve growth factor (NGF) mutein, HC201, in a mouse model of corneal nerve bed injury. The key goal is to evaluate whether topical treatment with HC201 more effectively improves tear film production and corneal sensitivity compared to wildtype NGF. This...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the University of Southern California to develop a monoclonal antibody targeting a specific post-translational modification (isoaspartylation) of the ELAVL4 protein, which is expressed on the surface of small cell lung cancer (SCLC) tumors. The key objectives are to: 1) Generate a mouse monoclonal antibody specifically targeting isoaspartylated ELAVL4, and 2) Test the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $300,000 to support pre-clinical IND-enabling studies for the recombinant ECD4-Ig protein therapeutic ahead of a first-in-human Phase 1 clinical trial. The key products and services to be delivered include in vitro assays required for an Investigational New Drug (IND) application submission, such as tissue...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $683,472 to the University of Cincinnati to develop and clinically evaluate the small molecule DHODH inhibitor HOSU-53 as a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to: Conduct the first-in-human Phase 1 clinical trial of HOSU-53 in AML, including pharmacokinetic and pharmacodynamic monitoring and utilizing single-cell DNA sequencing to track...